A detailed history of Jacobs Levy Equity Management, Inc transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Jacobs Levy Equity Management, Inc holds 524,168 shares of NBIX stock, worth $65.9 Million. This represents 0.24% of its overall portfolio holdings.

Number of Shares
524,168
Previous 721,087 27.31%
Holding current value
$65.9 Million
Previous $99.3 Million 39.21%
% of portfolio
0.24%
Previous 0.43%

Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$114.58 - $153.15 $22.6 Million - $30.2 Million
-196,919 Reduced 27.31%
524,168 $60.3 Million
Q2 2024

Aug 14, 2024

BUY
$130.86 - $143.19 $1.08 Million - $1.19 Million
8,289 Added 1.16%
721,087 $99.3 Million
Q1 2024

May 15, 2024

SELL
$130.4 - $143.74 $5.22 Million - $5.76 Million
-40,067 Reduced 5.32%
712,798 $98.3 Million
Q4 2023

Feb 14, 2024

BUY
$106.07 - $132.76 $6.42 Million - $8.03 Million
60,491 Added 8.74%
752,865 $99.2 Million
Q3 2023

Nov 16, 2023

BUY
$94.02 - $117.1 $24.2 Million - $30.1 Million
256,920 Added 59.0%
692,374 $77.9 Million
Q2 2023

Aug 14, 2023

BUY
$89.53 - $104.87 $368,684 - $431,854
4,118 Added 0.95%
435,454 $41.1 Million
Q1 2023

May 15, 2023

BUY
$94.11 - $123.02 $34.6 Million - $45.2 Million
367,229 Added 572.84%
431,336 $43.7 Million
Q4 2022

Feb 14, 2023

BUY
$106.72 - $127.06 $5.39 Million - $6.42 Million
50,540 Added 372.52%
64,107 $7.66 Million
Q3 2022

Nov 15, 2022

BUY
$92.03 - $107.81 $1.25 Million - $1.46 Million
13,567 New
13,567 $1.44 Million
Q1 2021

May 17, 2021

SELL
$87.57 - $119.4 $552,391 - $753,175
-6,308 Closed
0 $0
Q4 2020

Feb 16, 2021

SELL
$86.91 - $108.33 $2.19 Million - $2.73 Million
-25,173 Reduced 79.96%
6,308 $605,000
Q3 2020

Nov 16, 2020

BUY
$96.16 - $135.15 $379,543 - $533,437
3,947 Added 14.34%
31,481 $3.03 Million
Q2 2020

Aug 17, 2020

SELL
$85.09 - $130.36 $10.5 Million - $16 Million
-122,910 Reduced 81.7%
27,534 $3.36 Million
Q1 2020

May 15, 2020

SELL
$75.11 - $113.76 $855,352 - $1.3 Million
-11,388 Reduced 7.04%
150,444 $13 Million
Q4 2019

Feb 14, 2020

BUY
$86.8 - $118.57 $4.16 Million - $5.68 Million
47,903 Added 42.05%
161,832 $17.4 Million
Q3 2019

Nov 14, 2019

SELL
$83.82 - $101.5 $1.71 Million - $2.08 Million
-20,450 Reduced 15.22%
113,929 $10.3 Million
Q2 2019

Aug 13, 2019

BUY
$72.24 - $91.27 $3.63 Million - $4.58 Million
50,210 Added 59.65%
134,379 $11.3 Million
Q1 2019

May 14, 2019

BUY
$69.31 - $91.53 $5.83 Million - $7.7 Million
84,169 New
84,169 $7.42 Million

Others Institutions Holding NBIX

About NEUROCRINE BIOSCIENCES INC


  • Ticker NBIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 95,639,296
  • Market Cap $12B
  • Description
  • Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...
More about NBIX
Track This Portfolio

Track Jacobs Levy Equity Management, Inc Portfolio

Follow Jacobs Levy Equity Management, Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jacobs Levy Equity Management, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Jacobs Levy Equity Management, Inc with notifications on news.